Lipid risk factors and the regression of atherosclerosis Review uri icon

Overview

MeSH Major

  • Arteriosclerosis
  • Hypolipidemic Agents
  • Lipids

abstract

  • Angiographically monitored clinical trials of antilipidemic therapy have demonstrated that the progression of atherosclerosis may be slowed or even reversed. The clinical benefit observed in these trials strengthens the rationale for aggressive therapy in patients with known atherosclerotic disease. Additionally, these trials have provided further insight on the basis of clinical events and the risk factors associated with progression.

publication date

  • July 13, 1995

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 7604793

Additional Document Info

start page

  • 3A

end page

  • 7A

volume

  • 76

number

  • 2